<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6968587</article-id><article-id pub-id-type="pmid">31856610</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1705294</article-id><article-id pub-id-type="publisher-id">1705294</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Rapid Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Discovery of 3-alkyl-5-aryl-1-pyrimidyl-1<italic>H-</italic>pyrazole derivatives as a novel selective inhibitor scaffold of JNK3</article-title><alt-title alt-title-type="left-running-head">Y. Oh et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Youri</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Jang</surname><given-names>Miyoung</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Hyunwook</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Songyi</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Im</surname><given-names>Daseul</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Moon</surname><given-names>Hyungwoo</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Hah</surname><given-names>Jung-Mi</given-names></name><xref ref-type="aff" rid="AF0001"/><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><institution>College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University</institution>, <city>Ansan</city>, <country>Korea</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Jung-Mi Hah <email>jhah@hanyang.ac.kr</email><institution>College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University</institution>, <city>Ansan</city><postal-code>04763</postal-code>, <country>Korea</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>12</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><volume>35</volume><issue>1</issue><fpage seq="38">372</fpage><lpage>376</lpage><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_35_1705294.pdf"/><abstract><title>Abstract</title><p>3-alkyl-5-aryl-1-pyrimidyl-1<italic>H</italic>-pyrazole derivatives were designed and synthesised as selective inhibitors of JNK3, a target for the treatment of neurodegenerative diseases. Following previous studies, we have designed JNK3 inhibitors to reduce the molecular weight and successfully identified a lead compound that exhibits equipotent activity towards JNK3. Kinase profiling results also showed high selectivity for JNK3 among 38 kinases. Among the derivatives, the IC<sub>50</sub> value of <bold>8a,</bold> (<italic>R</italic>)-2-(1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-5-(3,4-dichlorophenyl)-1<italic>H</italic>-pyrazol-3-yl)acetonitrile exhibited 227&#x02009;nM, showing the highest inhibitory activity against JNK3.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>JNK</kwd><kwd>pyrazole</kwd><kwd>neurodegenerative diseases</kwd><kwd>SAR</kwd></kwd-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="5"/><word-count count="2092"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001" disp-level="1"><title>Introduction</title><p>c-Jun N-terminal Kinase (JNK) is a serine/threonine kinase that is one of the members of the mitogen-activated protein kinase (MAPK) family<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. Activation occurs as a result of stimulation by factors such as oxidative stress, cytokines, and ultraviolet rays, thus inducing the apoptosis pathway of cells<xref rid="CIT0002" ref-type="bibr"><sup>2&#x02013;6</sup></xref>. These JNKs have three isoforms. Among them, JNK1 and two are widely distributed in cells and tissues, but JNK3 is known to be distributed specifically in the brain<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>. These facts suggested that JNK3 may be a target for therapeutic agents for neurodegenerative diseases such as Alzheimer&#x02019;s and Parkinson&#x02019;s diseases<xref rid="CIT0008" ref-type="bibr"><sup>8&#x02013;10</sup></xref>. Through many studies, it has been shown that inhibiting JNK3 suppresses the formation of beta amyloid, one of the causes of Alzheimer&#x02019;s disease, and has proven its potential as a therapeutic target<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref>. However, all three JNK isoforms have an ATP binding pocket with a highly conserved sequence; thus far very few drugs that exhibit only high selectivity for JNK3 have been discovered<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. Due to the side effects that appear in response to these selectivity issues, there is increasing interest in research to find a JNK3-selective inhibitor.</p><p>We have found 1-heteroaryl-2-aryl-<italic>1H</italic>-benzimidazole derivatives that have selectivity for JNK3 through optimisation of a hit compound exhibiting JNK activity from our library in previous studies<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>. Based on the SAR results, we continued our efforts to design a new chemical scaffold of JNK3 inhibitors with reduced molecular weights for better Brain-Blood Barrier permeability<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. During the development of new JNK3-selective inhibitors, we sought to maintain three interactions of the previous scaffold; <italic>hydrogen bonds in the hinge region</italic>, <italic>hydrophobic interaction</italic> of the aromatic ring, and the <italic>hydrogen bond</italic> of phenol in the benzimidazole scaffold, thus attempting to reduce the molecular weight. Therefore, we discarded benzene from the benzimidazole scaffold, retaining the hydrogen bond-possible moiety on 5-membered ring with final design and synthesis of the 3-alkyl-5-aryl-1-pyrimidyl-1<italic>H</italic>-pyrazole derivatives (<xref ref-type="fig" rid="F0001">Figure 1</xref>).</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Docking structures of the previous JNK3 inhibitor (PDB: 3OY1) and design of the present 1-pyrimidyl-3-alkyl-5-aryl-1<italic>H</italic>-pyrazole scaffold.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1705294_F0001_C"/></fig></sec><sec sec-type="results" id="S0002" disp-level="1"><title>Results and discussion</title><p>The synthetic process of 3-alkyl-5-aryl-1-pyrimidyl-1<italic>H</italic>-pyrazole derivatives is shown in <xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>. We started with methyl ketones containing various aryl groups substituted (<bold>1</bold>) and formed enolate with sodium methoxide to react with dimethyl oxalate to produce beta ketone (<bold>2</bold>)<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>. The Knorr pyrazole synthesis was employed to form the pyrazole cores (<bold>3</bold>) using hydrazinyl pyrimidine and beta ketone<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>. After that, pyrazoyl ester was converted to alcohol (<bold>4</bold>) using lithium aluminium hydride<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>. The nitrile was introduced by the S<sub>N</sub>2 reaction with sodium cyanide following mesylation (<bold>5</bold>). Through the oxidation with potassium peroxymonosulfate of methyl sulphide to methylsulfone, a variety of amino groups were introduced to the pyrimidyl moiety (S<sub>N</sub>Ar)<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>; then the terminal amino group was deprotected and acylated to give the final products (<bold>7a&#x02013;d, 10a&#x02013;f</bold>). For compounds <bold>7e&#x02013;f</bold>, <bold>8a&#x02013;f</bold>, and <bold>9a&#x02013;f</bold>, cyclopropylcarboxylated amine were directly incorporated. The terminal nitrile group was changed to an ester (<bold>11a</bold>) and carboxamide (<bold>12a</bold>) through <xref ref-type="scheme" rid="SCH0002">Scheme 2</xref>. They were synthesised through hydrolysis of the <bold>10a</bold> performed at different conditions.</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of 3-alkyl-5-aryl-1-pyrimidyl-1<italic>H</italic>-pyrazole derivatives.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1705294_SCH0001_B"/></fig><fig id="SCH0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Synthesis of compound <bold>11a</bold> and <bold>12a</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1705294_SCH0002_B"/></fig><p>All of the synthesised compounds, <bold>7a</bold>&#x02013;<bold>7f</bold>, <bold>8a</bold>&#x02013;<bold>8f, 9a</bold>&#x02013;<bold>9f,</bold> and <bold>10a</bold>&#x02013;<bold>10f</bold> were evaluated for their inhibitory activity against JNK3 (<xref rid="t0001" ref-type="table">Table 1</xref>). First, we investigated the effect of the aryl group on their activity. The larger aryl groups such as the naphthyl and dichlorophenyl bound at position 5, elicited more potent activity towards JNK3 (<bold>a, b vs. e, f</bold>). This seems to be related to the electron density of the aromatic ring due to the sulfur-&#x003c0; interaction in the active site of JNK3. Compared to the mono-substituted phenyl groups, the relatively electron-rich dichlorophenyl and naphthyl groups could have formed a stronger &#x003c0;&#x02013;&#x003c0; interaction, which may affect the activity. Next, to investigate the effect of the substituent at position 3, the compound <bold>7a</bold> was hydrolysed to convert it to an amide and a methyl ester (<bold>11a, 12a</bold>). As a result, the existing nitrile was the best in terms of potency, but not a noticeable difference. In an effort to reduce the molecular weight, the piperidine ring was diversified into pyrrolidine and azetidine with less carbon atoms. Surprisingly, when (<italic>R</italic>)-aminopyrrolidine was coupled to the pyrimidyl group instead of the (<italic>S</italic>)-aminopiperidine, the activities were increased approximately two to three fold (<bold>7a vs 8a, 7b vs 8b, 7c vs 8c, 7d vs 8d</bold>). This also suggested that the configuration of the amino group in the ring should be considered important for binding, even in the solvent exposure part for optimal extra-hydrogen bonding. The extra hydrogen bonding seemed more plausible in (<italic>R</italic>)-pyrrolidine (<bold>8</bold>) than in both cases of (<italic>S</italic>)-piperidine (<bold>7</bold>) and (<italic>S</italic>)-pyrrolidine (<bold>9</bold>) in the docking structures (<xref ref-type="fig" rid="F0002">Figure 2</xref>).</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Comparison of docking structures of <bold>7a</bold> and <bold>8a</bold> at JNK3 (PDB: 3OY1).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1705294_F0002_C"/></fig><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Enzymatic activities of 1-heteroaryl-3-alkyl-5-aryl-1H-pyrazole derivatives. <inline-graphic xlink:href="IENZ_A_1705294_ILG0001_B.jpg" content-type="black-white"/></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">No</th><th align="center">Ar</th><th align="center"><italic toggle="yes">n</italic></th><th align="center">*(R/S)</th><th align="center">R</th><th align="center">JNK3 IC<sub>50</sub> (&#x003bc;M)</th><th align="center">No</th><th align="center">Ar</th><th align="center"><italic toggle="yes">n</italic></th><th align="center">*(R/S)</th><th align="center">R</th><th align="center">JNK3 IC<sub>50</sub> (&#x003bc;M)</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>7a</bold></td><td rowspan="6"><inline-graphic xlink:href="IENZ_A_1705294_ILG0002_B.gif" content-type="black-white"/></td><td align="left">3</td><td align="center"><italic toggle="yes">S</italic></td><td align="center">CN</td><td align="center">0.635</td><td align="left"><bold>7b</bold></td><td rowspan="4"><inline-graphic xlink:href="IENZ_A_1705294_ILG0003_B.gif" content-type="black-white"/></td><td align="left">3</td><td align="center"><italic toggle="yes">S</italic></td><td align="left">CN</td><td align="char" char=".">0.824</td></tr><tr><td align="left"><bold>8a</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">R</italic></td><td align="center">CN</td><td align="center">0.227</td><td align="left"><bold>8b</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">R</italic></td><td align="left">CN</td><td align="char" char=".">0.361</td></tr><tr><td align="left"><bold>9a</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">S</italic></td><td align="center">CN</td><td align="center">3.11</td><td align="left"><bold>9b</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">S</italic></td><td align="left">CN</td><td align="char" char=".">2.90</td></tr><tr><td align="left"><bold>10a</bold></td><td align="left">1</td><td align="center"><italic toggle="yes">-</italic></td><td align="center">CN</td><td align="center">2.84</td><td align="left"><bold>10b</bold></td><td align="left">1</td><td align="center"><italic toggle="yes">-</italic></td><td align="left">CN</td><td align="char" char=".">2.07</td></tr><tr><td align="left"><bold>11a</bold></td><td align="left">3</td><td align="center"><italic toggle="yes">S</italic></td><td align="center">CONH<sub>2</sub></td><td align="center">1.46</td><td rowspan="2" colspan="6">&#x000a0;</td></tr><tr><td align="left"><bold>12a</bold></td><td align="left">3</td><td align="center"><italic toggle="yes">S</italic></td><td align="center">CO<sub>2</sub>Me</td><td align="center">0.903</td></tr><tr><td align="left"><bold>7c</bold></td><td rowspan="4"><inline-graphic xlink:href="IENZ_A_1705294_ILG0004_B.gif" content-type="black-white"/></td><td align="left">3</td><td align="center"><italic toggle="yes">S</italic></td><td align="center">CN</td><td align="center">4.60</td><td align="left"><bold>7d</bold></td><td rowspan="4"><inline-graphic xlink:href="IENZ_A_1705294_ILG0005_B.gif" content-type="black-white"/></td><td align="left">3</td><td align="center"><italic toggle="yes">S</italic></td><td align="left">CN</td><td align="char" char=".">7.90</td></tr><tr><td align="left"><bold>8c</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">R</italic></td><td align="center">CN</td><td align="center">2.18</td><td align="left"><bold>8d</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">R</italic></td><td align="left">CN</td><td align="char" char=".">4.42</td></tr><tr><td align="left"><bold>9c</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">S</italic></td><td align="center">CN</td><td align="center">8.57</td><td align="left"><bold>9d</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">S</italic></td><td align="left">CN</td><td align="char" char=".">3.25</td></tr><tr><td align="left"><bold>10c</bold></td><td align="left">1</td><td align="center"><italic toggle="yes">-</italic></td><td align="center">CN</td><td align="center">5.58</td><td align="left"><bold>10d</bold></td><td align="left">1</td><td align="center"><italic toggle="yes">-</italic></td><td align="left">CN</td><td align="center">NA</td></tr><tr><td align="left"><bold>7e</bold></td><td rowspan="4"><inline-graphic xlink:href="IENZ_A_1705294_ILG0006_B.gif" content-type="black-white"/></td><td align="left">3</td><td align="center"><italic toggle="yes">S</italic></td><td align="center">CN</td><td align="center">NA</td><td align="left"><bold>7f</bold></td><td rowspan="4"><inline-graphic xlink:href="IENZ_A_1705294_ILG0007_B.gif" content-type="black-white"/></td><td align="left">3</td><td align="center"><italic toggle="yes">S</italic></td><td align="left">CN</td><td align="center">&#x0003e;10</td></tr><tr><td align="left"><bold>8e</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">R</italic></td><td align="center">CN</td><td align="center">&#x0003e;10</td><td align="left"><bold>8f</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">R</italic></td><td align="left">CN</td><td align="char" char=".">7.89</td></tr><tr><td align="left"><bold>9e</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">S</italic></td><td align="center">CN</td><td align="center">NA</td><td align="left"><bold>9f</bold></td><td align="left">2</td><td align="center"><italic toggle="yes">S</italic></td><td align="left">CN</td><td align="center">NA</td></tr><tr><td align="left"><bold>10e</bold></td><td align="left">1</td><td align="center"><italic toggle="yes">-</italic></td><td align="center">CN</td><td align="center">NA</td><td align="left"><bold>10f</bold></td><td align="left">1</td><td align="center"><italic toggle="yes">-</italic></td><td align="left">CN</td><td align="center">NA</td></tr><tr><td colspan="5" align="center">Control compound</td><td colspan="6" align="center">JNKI VIII<xref ref-type="bibr" rid="CIT0020"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="CIT0021"><sup>21</sup></xref></td><td align="char" char=".">0.005</td></tr></tbody></table></table-wrap><p>Next, we used kinase panel screening in duplicate for compound <bold>7a</bold> over 38 different kinases at a single-dose concentration of 10&#x02009;&#x003bc;M (<xref rid="t0002" ref-type="table">Table 2</xref>). The compound was indeed a selective JNK3 inhibitor with an excellent selectivity profile. This compound has an inhibitory activity of 90% on JNK3 at a concentration of 10&#x02009;&#x003bc;M; the inhibition activity was less than 20% for most other kinases except GSK3&#x003b2;, but for which, was also six fold selective in terms of IC<sub>50</sub>.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Percentages of enzymatic inhibition exerted by <bold>7a</bold> (10&#x02009;&#x003bc;M) on 38 selected protein kinases and enzymatic activities on selected protein kinases. <inline-graphic xlink:href="IENZ_A_1705294_ILG0008_C.jpg" content-type="color"/></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="2" align="center">Compound IC<sub>50</sub>* (M):<hr/></th><th rowspan="2" align="center">IC<sub>50</sub> (nM) Control Cmpd</th><th rowspan="2" align="center">Control Cmpd ID</th></tr><tr><th align="left">Kinase:</th><th align="center"><bold>7a</bold></th></tr></thead><tbody valign="top"><tr><td align="left">GSK3&#x003b2;</td><td align="char" char=".">3.96</td><td align="char" char=".">2.30</td><td align="left">Staurosporine</td></tr><tr><td align="left">JNK3</td><td align="char" char=".">0.635</td><td align="char" char=".">5.13</td><td align="left">JNKi VIII</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>We used Reaction Biology Corp. <italic>Kinase HotSpot</italic><sup>SM</sup> service (<ext-link ext-link-type="uri" xlink:href="http://www.reactionbiology.com">www.reactionbiology.com</ext-link>) for screening of <bold>7a</bold>.</p></fn></table-wrap-foot></table-wrap><p>A docking study was conducted to understand the binding mode of the novel JNK3 inhibitors (<xref ref-type="fig" rid="F0003">Figure 3</xref>). When we performed the docking experiment of <bold>8a</bold> with a known JNK3 structure (3OY1), it was shown that many of the interactions could contribute to complex stabilisation. First, the amino pyrimidine used as the hinge binder was found to form two hydrogen bonds with Met149 of JNK3 and another hydrogen bond is plausible between the oxygen of the cyclopropyl carboxamide group in <bold>8a</bold> and Gln155 in the extended hinge region. The third hydrogen bond seems possible between the nitrile located in the three position of pyrazole, which forms two hydrogen bonds between the backbone and the side chain of Asn152. Lastly, the aryl group at position 1 of pyrazole also fits into the hydrophobic pocket formed by residues such as Met148, Val79, Val145, Leu144, Ala91, Ile92, Ile124 and Leu128, especially noting that the dichlorophenyl ring could form a halogen bond with Lys93.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Docking structures of <bold>8a</bold> at JNK3 (PDB: 3OY1) and 2&#x02009;D-interaction map.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1705294_F0003_C"/></fig></sec><sec sec-type="conclusions" id="S0003" disp-level="1"><title>Conclusions</title><p>We have successfully synthesised 3-alkyl-5-aryl-1-pyrimidyl-1<italic>H</italic>-pyrazole derivatives that were designed as novel JNK3 selective inhibitors in an effort to reduce the molecular weight from previous lead. Twenty-six compounds were synthesised and measured for their enzyme activity against JNK3. Particularly, compounds <bold>7a, 7b, 8a,</bold> and <bold>8b</bold> showed competitive activities against JNK3 with IC<sub>50</sub> values of 0.635&#x02009;&#x003bc;M, 0.824&#x02009;&#x003bc;M, 0.227&#x02009;&#x003bc;M, and 0.361&#x02009;&#x003bc;M, respectively. Compound <bold>7a</bold> was, indeed, a selective JNK3 inhibitor with an excellent selectivity profile, especially compared to the activity towards similar protein kinases such as p38&#x003b1;, GSK&#x003b2;, Erk, JNK1, and JNK2. We believe that this novel scaffold, 3-alkyl-5-aryl-1-pyrimidyl-1<italic>H</italic>-pyrazole will be highly useful in the development of JNK3 selective inhibitors, as therapeutic agents for neurodegenerative diseases.</p></sec></body><back><sec id="S0004" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>RJ.</given-names></name></person-group>
<article-title>Signal transduction by the JNK Group of MAP kinases</article-title>. <source>Cell</source>
<year>2000</year>;<volume>103</volume>:<fpage>239</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">11057897</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>P</given-names></name>, <name name-style="western"><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name></person-group>
<article-title>New insights into the structural dynamics of the kinase JNK3</article-title>. <source>Sci Rep</source>
<year>2018</year>;<volume>8</volume>:<fpage>9435</fpage>.<pub-id pub-id-type="pmid">29930333</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyriakis</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Banerjee</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Nikolakaki</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The stress-activated protein kinase subfamily of c-Jun kinases</article-title>. <source>Nature</source>
<year>1994</year>;<volume>369</volume>:<fpage>156</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">8177321</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogoyevitch</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Ngoei</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>TT</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges</article-title>. <source>Biochim Biophys Acta</source>
<year>2010</year>;<volume>1804</volume>:<fpage>463</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">19900593</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haeusgen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Boehm</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Specific activities of individual c-Jun N-terminal kinases in the brain</article-title>. <source>Neuroscience</source>
<year>2009</year>;<volume>161</volume>:<fpage>951</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19364525</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weston</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>RJ.</given-names></name></person-group>
<article-title>The JNK signal transduction pathway</article-title>. <source>Curr Opin Cell Biol</source>
<year>2007</year>;<volume>19</volume>:<fpage>142</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17303404</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Barrett</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Whitmarsh</surname><given-names>AJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selective interaction of JNK protein kinase isoforms with transcription factors</article-title>. <source>Embo J</source>
<year>1996</year>;<volume>15</volume>:<fpage>2760</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">8654373</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antoniou</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Falconi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Di Marino</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Borsello</surname><given-names>T.</given-names></name></person-group>
<article-title>JNK3 as a therapeutic target for neurodegenerative diseases</article-title>. <source>J Alzheimer Dis</source>
<year>2011</year>;<volume>24</volume>:<fpage>633</fpage>&#x02013;<lpage>42</lpage>.</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dou</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Multistage screening reveals 3-substituted indolin-2-one derivatives as novel and isoform-selective c-Jun N-terminal Kinase 3 (JNK3) inhibitors: implications to drug discovery for potential treatment of neurodegenerative diseases</article-title>. <source>J Med Chem</source>
<year>2019</year>;<volume>62</volume>:<fpage>6645</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">31268308</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gehringer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Laufer</surname><given-names>SA.</given-names></name></person-group>
<article-title>Inhibitors of c-Jun N-terminal kinases: an update</article-title>. <source>J Med Chem</source>
<year>2015</year>;<volume>58</volume>:<fpage>72</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">25415535</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flemming</surname><given-names>A.</given-names></name></person-group>
<article-title>JNK3 as new target in AD?</article-title>
<source>Nat Rev Drug Discov</source>
<year>2012</year>;<volume>11</volume>:<fpage>829</fpage>.<pub-id pub-id-type="pmid">23123935</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hah</surname><given-names>JM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1&#x02009;H -benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects</article-title>. <source>Bioorg Med Chem</source>
<year>2013</year>;<volume>21</volume>:<fpage>2271</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">23498914</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fong</surname><given-names>CW.</given-names></name></person-group>
<article-title>Permeability of the blood&#x02013;brain barrier: molecular mechanism of transport of drugs and physiologically important compounds</article-title>. <source>J Membr Biol</source>
<year>2015</year>;<volume>248</volume>:<fpage>651</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">25675910</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geldenhuys</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Mohammad</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Adkins</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Lockman</surname><given-names>PR.</given-names></name></person-group>
<article-title>Molecular determinants of blood&#x02013;brain barrier permeation</article-title>. <source>Ther Deliv</source>
<year>2015</year>;<volume>6</volume>:<fpage>961</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">26305616</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and acrosin inhibitory activities of 5-phenyl-1H-pyrazole-3-carboxylic acid amide derivatives</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2013</year>;<volume>23</volume>:<fpage>4177</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">23746472</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gosselin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>O&#x02019;Shea</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Webster</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Highly regioselective synthesis of 1-Aryl-3,4,5-substituted pyrazoles</article-title>. <source>Synlett</source>
<year>2006</year>;<volume>2006</volume>:<fpage>3267</fpage>&#x02013;<lpage>70</lpage>.</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>SZ</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>ZC</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>XH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition</article-title>. <source>Bioorg Med Chem</source>
<year>2018</year>;<volume>26</volume>:<fpage>4264</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">30031652</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odell</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Abdel-Hamid</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>TA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pyrimidine-based inhibitors of dynamin I GTPase activity: competitive inhibition at the Pleckstrin Homology domain</article-title>. <source>J Med Chem</source>
<year>2017</year>;<volume>60</volume>:<fpage>349</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">27997171</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaulieu</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Bousquet</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gauthier</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 Cells</article-title>. <source>J Med Chem</source>
<year>2004</year>;<volume>47</volume>:<fpage>6884</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">15615537</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vivanco</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Palaskas</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tran</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN</article-title>. <source>Cancer Cell</source>
<year>2007</year>;<volume>11</volume>:<fpage>555</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">17560336</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szczepankiewicz</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Kosogof</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>LTJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity</article-title>. <source>J Med Chem</source>
<year>2006</year>;<volume>49</volume>:<fpage>3563</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">16759099</pub-id></mixed-citation></ref></ref-list></back></article>